CSL shares are back below $100 after a brutal sell-off. The post Under $100, are CSL shares finally too cheap to ignore? appeared first on The Motley Fool Australia.

Bearish drivers for Sanofi based on current data, valuation, sector breadth, and scenario-based downside conditions.

On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 ...

On May 15, Alex Guiliano, CIO of Resonate Wealth Partners, joined BNN Bloomberg to suggest that valuations internationally ...

Novartis outlook for 2027 using current valuation, company guidance, institutional inputs, and scenario-based price ranges.

A lot of investors tend to think about the S&P 500 index as one giant monolith, but I think it becomes much more interesting ...

Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company focuses on creating a fair healthcare ecosystem, to ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

When it comes to growth stocks, much of the attention often centers around tech. But there are potentially much better ...

Picture an excessively mobile middle-class family that does almost nothing but drive, traveling from New York City to Los Angeles and back again each week. Its gasoline bill, instead of taking up a ...

Whether tech stocks can continue generating stellar earnings into the future is a hot topic among analysts at present. Morningstar found that the AI theme is trading at its largest discount since 2019 ...

This episode was filmed Wednesday 6th May 2026. It starts with nothing. A minor ache here, an odd pain there. It lingers…strange, but not alarming enough to call the doctor. Not yet. So you make the ...